Introduction Late night infomercials and the internet “inform” the public that there are treatments and cures that “they don’t want you to know about”. Included in these treatments is the use of human chorionic gonadotropin for the treatment of obesity. The basis for this proposed therapy is a 1954 article by Simeons who introduced the concept of a combination of a strictly restricted diet plus the daily administration of low doses of human chorionic gonadotropin (hCG) for the treatment of obesity. (1) The controversies and scant scientific literature did not dissuade its early use and led to a Guest Editiorial in the American Journal of Clinical Nutrition by Margaret Albrink in 1969 in which she felt that the subject should be considered in three parts: 1) Whether this treatment helps to bring about acute weight loss; 2) The usefulness in long-range treatment of obesity; and 3) The possible mechanism of action of hCG in obesity. (2) Well designed studies to answer these questions were encouraged.